Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00220779 · ClinicalTrials.gov registry record · Phase 2
Immune Globulin Intravenous (IGIV) To Treat Relapsing, Remitting Multiple Sclerosis
A Phase 2 study, sponsored by Grifols Therapeutics.
- Completed
- Registry status
- Phase 2
- Development phase
- 128
- Enrollment target
NCT00220779 is a Phase 2 study that has completed, run by Grifols Therapeutics. The registered enrollment target is 128 participants.
The verdict
NCT00220779, a Phase 2 study, has completed, sponsored by Grifols Therapeutics.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 128 participants
- Enrollment target
Study Summary
The trial will study 2 doses of Immune Globulin Intravenous (Human), 10% Caprylate/Chromatography Purified (IGIV-C) for the number of relapses that occur in a 1 year treatment period.
Interventions
- DRUG Immune Globulin IV [Human], 10% Caprylate/Chromatography Purified
- DRUG Albumin (Human) 25%, United States Pharmacopeia (USP)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 128 participants |
| Start Date | 2002-12 |
| Est. Completion | 2005-02 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00220779
The ClinicalTrials.gov registry entry for NCT00220779 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 128 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Grifols Therapeutics, which has 34 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Immune Globulin IV [Human], 10% Caprylate/Chromatography Purified is the first listed.
NCT00220779 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00220779 about?
NCT00220779 is a clinical study titled "Immune Globulin Intravenous (IGIV) To Treat Relapsing, Remitting Multiple Sclerosis". The trial will study 2 doses of Immune Globulin Intravenous (Human), 10% Caprylate/Chromatography Purified (IGIV-C) for the number of relapses that occur in a 1 year treatment period.
What is the current status of trial NCT00220779?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 128 participants. The study started on 2002-12. Estimated completion is 2005-02.
What interventions are being tested in trial NCT00220779?
The interventions under investigation include: Immune Globulin IV [Human], 10% Caprylate/Chromatography Purified (DRUG), Albumin (Human) 25%, United States Pharmacopeia (USP) (DRUG).
Who is sponsoring clinical trial NCT00220779?
This trial is sponsored by Grifols Therapeutics, which has 34 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.